ArticleJournal of cancer survivorship : research and practice2026
Examining HPV vaccination coverage among childhood, adolescent, and young adult cancer survivors: a report from the St. Jude Lifetime Cohort study.
Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeChildhood, adolescent, and young adult (CAYA) cancer survivors are at risk of HPV-related cancers, yet HPV vaccination remains lower than in the general population. The purpose of this study was to examine HPV vaccination initiation and completion among CAYA survivors and to assess the influence of sociodemographic and cancer-specific factors on vaccination.
methodsWe used data from the St. Jude Lifetime Cohort, 5 + year cancer survivors, treated at St. Jude Children's Research Hospital, eligible for HPV vaccination since 2006 (year of FDA licensure in the USA). Primary outcomes were HPV vaccination initiation and completion. HPV vaccination was assessed between 2011 and 2020. We performed descriptive statistics and evaluated associations using univariate and multivariable logistic regression analysis using SAS version 9.4.
resultsWe included 2907 CAYA survivors. HPV vaccination initiation was reported by 27.31% survivors. Among those who initiated, 71.16% survivors completed vaccination series. Female survivors compared to male survivors (OR, 2.58; 95% CI, 2.10-3.17), those age 27 + compared to 9-17 years (OR, 0.21; 95% CI, 0.10-0.42), those with a college degree or higher compared to those with a high school degree (OR, 2.39; 95% CI, 1.40-4.06), and those with insurance compared to those without insurance (public, OR, 2.00; 95% CI, 1.22-3.28; private, OR, 2.26; 95% CI, 1.41-3.63) had higher vaccination initiation. Cancer diagnosed at a later age (9-14 years, OR, 1.59; 95% CI, 1.20-2.09; 15-24 years, OR, 2.01; 95% CI, 1.40-2.90) had higher vaccination initiation than those diagnosed < 9 years.
conclusionsHPV vaccination was low among survivors. We found differences in vaccination by age, sex, education, insurance coverage, and age at cancer diagnosis. IMPLICATIONS FOR CANCER SURVIVORS: These findings provide evidence to guide the development of strategies for improving HPV vaccination and reducing the risk of HPV-related cancers among survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.